Product nameAnti-Perforin antibody [CB5.4]
See all Perforin primary antibodies
DescriptionRat monoclonal [CB5.4] to Perforin
Tested applicationsSuitable for: WB, IHC-Fr, IHC-P, ICC, IP, ICC/IFmore details
Species reactivityReacts with: Mouse
Recombinant fragment, corresponding to amino acids 98 - 534 of Mouse Perforin.
EpitopeThis antibody recognizes mouse perforin, region amino acids 402-534.
Storage instructionsShipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid repeated freeze / thaw cycles.
Storage bufferPreservative: 0.02% Sodium azide
Concentration information loading...
Purity>95% by SDS-PAGE
Our Abpromise guarantee covers the use of ab16074 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||Use a concentration of 1 µg/ml. Detects a band of approximately 66 kDa (predicted molecular weight: 66 kDa).|
|IHC-Fr||Use at an assay dependent concentration.|
|IHC-P||Use at an assay dependent concentration.|
|ICC||Use a concentration of 5 µg/ml.|
|IP||Use at an assay dependent concentration.|
|ICC/IF||Use at an assay dependent concentration.|
FunctionPlays a key role in secretory granule-dependent cell death, and in defense against virus-infected or neoplastic cells. Plays an important role in killing other cells that are recognized as non-self by the immune system, e.g. in transplant rejection or some forms of autoimmune disease. Can insert into the membrane of target cells in its calcium-bound form, oligomerize and form large pores. Promotes cytolysis and apoptosis of target cells by facilitating the uptake of cytotoxic granzymes.
Involvement in diseaseDefects in PRF1 are the cause of hemophagocytic lymphohistiocytosis familial type 2 (FHL2) [MIM:603553]; also known as HPLH2. Familial hemophagocytic lymphohistiocytosis (FHL) is a genetically heterogeneous, rare autosomal recessive disorder. It is characterized by immune dysregulation with hypercytokinemia and defective natural killer cell function. The clinical features of the disease include fever, hepatosplenomegaly, cytopenia, hypertriglyceridemia, hypofibrinogenemia, and neurological abnormalities ranging from irritability and hypotonia to seizures, cranial nerve deficits, and ataxia. Hemophagocytosis is a prominent feature of the disease, and a non-malignant infiltration of macrophages and activated T lymphocytes in lymph nodes, spleen, and other organs is also found.
Sequence similaritiesBelongs to the complement C6/C7/C8/C9 family.
Contains 1 C2 domain.
Contains 1 EGF-like domain.
Contains 1 MACPF domain.
DomainThe C2 domain mediates calcium-dependent binding to lipid membranes. A subsequent conformation change leads to membrane insertion of beta-hairpin structures and pore formation. The pore is formed by transmembrane beta-strands.
Cellular localizationCytoplasmic granule lumen. Secreted. Cell membrane. Endosome lumen. Stored in cytoplasmic granules of cytolytic T-lymphocytes and secreted into the cleft between T-lymphocyte and target cell. Inserts into the cell membrane of target cells and forms pores. Membrane insertion and pore formation requires a major conformation change. May be taken up via endocytosis involving clathrin-coated vesicles and accumulate in a first time in large early endosomes.
- Information by UniProt
- Cytolysin antibody
- FLH2 antibody
- HPLH2 antibody
ab16074 staining Perforin in Mouse lymphoid tissue sections by Immunohistochemistry (IHC-P - paraformaldehyde-fixed, paraffin-embedded sections). Tissue was fixed with a zinc-based fixative and blocked with rodent block-M for 20 minutes at 20°C. Samples were incubated with primary antibody (1/50 in TBS + 0.05% Tween20) for 1 hour at 20°C. A HRP-conjugated Goat polyclonal was used as the secondary antibody.
This product has been referenced in:
- Wijesundara DK et al. Induction of Genotype Cross-Reactive, Hepatitis C Virus-Specific, Cell-Mediated Immunity in DNA-Vaccinated Mice. J Virol 92:N/A (2018). Read more (PubMed: 29437963) »
- Lu J et al. Nano-enabled pancreas cancer immunotherapy using immunogenic cell death and reversing immunosuppression. Nat Commun 8:1811 (2017). Read more (PubMed: 29180759) »